Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia, respectively. The rare disease company is seeking a successor.

Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) said President and CEO Werner Cautreels will retire, effective Dec. 31, 2018. Selecta is seeking a successor. The company also appointed Omid Farokhzad chairman of

Read the full 785 word article

User Sign In